Sweden's Medical Products Agency (MPA) recently issued a report
calling for tougher environmental standards for pharmaceutical
production within the EU. The report addresses concerns over the
environmental impact of pharmaceutical production in low-cost countries,
such as India and China. “Today a considerable share of pharmaceutical
manufacturing and production of raw materials and semi-products takes
place in low-cost countries, and many large companies plan to locate
even more of their production there. In the first decade of the 21st
century, Swedish research findings have revealed emissions from the
manufacturing of pharmaceuticals in India on a scale that can seriously
impact the health of humans and animals, as well as the environment,”
according to an MPA statement.
Read more: